The circumstances surrounding the review and delayed approval of Amylin Pharmaceuticals Inc.’s Bydureon highlight the manufacturing challenges that lie ahead for companies moving into the biosimilar space.
Use of an exenatide extended-release (LAR) formulation in the Bydureon clinical development program that differed from the proposed commercial formulation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?